Literature DB >> 35411237

KMT2D loss drives aggressive tumor phenotypes in cutaneous squamous cell carcinoma.

Cara Dauch1, Sharon Shim2, Matthew Wyatt Cole1,3, Nijole C Pollock1, Abigail J Beer1, Johnny Ramroop1, Victoria Klee4, Dawn C Allain4, Reena Shakya5, Sue E Knoblaugh6, Jesse Kulewsky7, Amanda Ewart Toland1,4,5.   

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most lethal skin cancer. Due to ultraviolet light-induced damage, cSCCs have a high mutation rate, but some genes are more frequently mutated in aggressive cSCCs. Lysine-specific histone methyltransferase 2D (KMT2D) has a two-fold higher mutation frequency in metastatic cSCCs relative to primary non-metastatic associated cSCCs. The role of KMT2D in more aggressive phenotypes in cSCC is uncharacterized. Studies of other tumor types suggest that KMT2D acts to suppress tumor development. To determine whether KMT2D loss has an impact on tumor characteristics, we disrupted KMT2D in a cSCC cell line using CRISPR-cas9 and performed phenotypic analyses. KMT2D loss modestly increased cell proliferation and colony formation (1.4- and 1.6-fold respectively). Cells lacking KMT2D showed increased rates of migration and faster cell cycle progression. In xenograft models, tumors with KMT2D loss showed slight increases in mitotic indices. Collectively, these findings suggest that KMT2D loss-of-function mutations may promote more aggressive and invasive behaviors in cSCC, suggesting that KMT2D-related pathways could be targets for cancer therapies. Future studies to determine the downstream genes and mechanism of phenotypic effect are needed. AJCR
Copyright © 2022.

Entities:  

Keywords:  Cutaneous squamous cell carcinoma; KMT2D; cSCC; metastasis; skin cancer

Year:  2022        PMID: 35411237      PMCID: PMC8984905     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  42 in total

1.  Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.

Authors:  Rami N Al-Rohil; Ashley J Tarasen; J Andrew Carlson; Kai Wang; Adrienne Johnson; Roman Yelensky; Doron Lipson; Julia A Elvin; Jo-Anne Vergilio; Siraj M Ali; James Suh; Vincent A Miller; Philip J Stephens; Prasanth Ganesan; Filip Janku; Daniel D Karp; Vivek Subbiah; Martin C Mihm; Jeffrey S Ross
Journal:  Cancer       Date:  2015-10-19       Impact factor: 6.860

2.  Genomic analysis of metastatic cutaneous squamous cell carcinoma.

Authors:  Yvonne Y Li; Glenn J Hanna; Alvaro C Laga; Robert I Haddad; Jochen H Lorch; Peter S Hammerman
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

Review 3.  Keratinocyte Carcinomas: Current Concepts and Future Research Priorities.

Authors:  Priyadharsini Nagarajan; Maryam M Asgari; Adele C Green; Samantha M Guhan; Sarah T Arron; Charlotte M Proby; Dana E Rollison; Catherine A Harwood; Amanda Ewart Toland
Journal:  Clin Cancer Res       Date:  2018-12-06       Impact factor: 12.531

4.  Loss of the Vitamin D Receptor in Human Breast Cancer Cells Promotes Epithelial to Mesenchymal Cell Transition and Skeletal Colonization.

Authors:  Konstantin Horas; Yu Zheng; Colette Fong-Yee; Eugenie Macfarlane; Jeline Manibo; Yunzhao Chen; Jeremy Qiao; Mingxuan Gao; Nancy Haydar; Michelle M McDonald; Peter I Croucher; Hong Zhou; Markus J Seibel
Journal:  J Bone Miner Res       Date:  2019-06-25       Impact factor: 6.741

5.  Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study.

Authors:  Chrysalyne D Schmults; Pritesh S Karia; Joi B Carter; Jiali Han; Abrar A Qureshi
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

Review 6.  Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma.

Authors:  T J Willenbrink; A Jambusaria-Pahlajani; S Arron; D Seckin; C A Harwood; C M Proby
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-12       Impact factor: 6.166

7.  A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes.

Authors:  Franz Oswald; Patrick Rodriguez; Benedetto Daniele Giaimo; Zeus A Antonello; Laura Mira; Gerhard Mittler; Verena N Thiel; Kelly J Collins; Nassif Tabaja; Wiebke Cizelsky; Melanie Rothe; Susanne J Kühl; Michael Kühl; Francesca Ferrante; Kerstin Hein; Rhett A Kovall; Maria Dominguez; Tilman Borggrefe
Journal:  Nucleic Acids Res       Date:  2016-02-23       Impact factor: 16.971

8.  KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis.

Authors:  Enrique Lin-Shiao; Brian C Capell; Yemin Lan; Mariel Coradin; Amy Anderson; Greg Donahue; Cory L Simpson; Payel Sen; Rizwan Saffie; Luca Busino; Benjamin A Garcia; Shelley L Berger
Journal:  Genes Dev       Date:  2018-02-12       Impact factor: 11.361

9.  KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.

Authors:  Si-Si Li; Wei-Liang Jiang; Wen-Qin Xiao; Kai Li; Ye-Fei Zhang; Xing-Ya Guo; Yi-Qi Dai; Qiu-Yan Zhao; Ming-Jie Jiang; Zhan-Jun Lu; Rong Wan
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

Review 10.  The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets.

Authors:  Yizheng Yao; Ying Ni; Jiawen Zhang; Hua Wang; Shihe Shao
Journal:  Oncotarget       Date:  2017-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.